TRT community content: separating hype from clinical evidence

What did @calxshreds actually say?

The creator describes starting self-prescribed TRT at 150mg per week after being diagnosed with hypogonadism, reaching levels he describes as "33mm L" (almost certainly 33 nmol/L, which is roughly 950 ng/dL). He says his life improved "in every single way imaginable" and then makes two broader claims worth scrutinizing: that any man over 30 or any man with low testosterone should be on TRT, and that "65% of men likely just need TRT" instead of SSRIs for depression. The personal story is credible. The sweeping generalizations are not.

He also explicitly frames this as "true TRT" to distinguish it from performance-enhancing drug use, which is a distinction worth taking seriously, even if his dosing approach blurs that line.

Does the science back this up?

For men with clinically confirmed hypogonadism, yes, TRT has solid evidence behind it. The benefits he describes are real and documented. But the "every man over 30" claim and the 65% SSRI statistic have no credible sourcing.

A 2023 landmark trial published in the New England Journal of Medicine, the TRAVERSE study (Lincoff et al., 2023), confirmed that testosterone therapy in men with hypogonadism and cardiovascular risk factors was non-inferior to placebo for major cardiac events. That is genuinely reassuring safety news. Earlier work by Snyder et al. (2016, NEJM) in the Testosterone Trials showed meaningful improvements in sexual function, mood, and bone density in older hypogonadal men. So the core claim that TRT improves quality of life for men with genuinely low testosterone is well-supported. The extrapolation to all men over 30 is not supported by any of this evidence.

On the SSRI vs. TRT comparison, there is some interesting research. Zarrouf et al. (2009, Journal of Psychiatric Practice) found testosterone therapy improved depressive symptoms in hypogonadal men, but this does not mean 65% of depressed men need testosterone instead of antidepressants. That figure appears to be invented.

What did they get wrong (or right)?

Credit where it is due: describing hypogonadism as affecting confidence, physique, mood, and energy is accurate. Those are the recognized symptoms in clinical guidelines from the Endocrine Society (Bhasin et al., 2018). Starting at 150mg per week and landing around 950 ng/dL (33 nmol/L) is plausible and not an outrageous dose in clinical context, though it sits at the upper end of what most endocrinologists would target.

What he got wrong:

• "Any man over the age of 30 should be on TRT" is not supported by evidence and contradicts clinical guidelines, which require documented low levels plus symptoms before treatment is appropriate.
• The 65% SSRI claim appears to be entirely fabricated. There is no peer-reviewed data supporting this figure.
• Self-prescribing TRT is a red flag he glosses over. Unsupervised testosterone use carries real risks including erythrocytosis, infertility, and suppression of the hypothalamic-pituitary-gonadal axis.
• Calling TRT "very very healthy" as a blanket statement oversimplifies the risk profile, particularly for men who want to preserve fertility.

What should you actually know?

If your testosterone is genuinely around 200 ng/dL and you feel consistently fatigued, the right first move is a proper workup, not a TikTok comment section. Two separate morning blood draws are the standard starting point, along with LH, FSH, and prolactin to figure out whether the problem is in the testes or upstream in the pituitary.

TRT, when appropriately prescribed for confirmed hypogonadism, can meaningfully improve energy, mood, body composition, and libido. The evidence for this is real. But the decision involves tradeoffs: fertility suppression is nearly universal on exogenous testosterone, cardiovascular monitoring is required, and hematocrit needs to be checked regularly.

The creator's personal story is probably genuine. But personal stories, even compelling ones, are not clinical data. A man whose levels were 200 ng/dL and who felt terrible responding well to TRT tells you nothing reliable about whether a man at 350 ng/dL with vague fatigue would benefit the same way. Context matters enormously in hormone medicine, and that nuance is entirely absent here.